The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1301
A Granisetron Patch (Sancuso)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant1 plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso – ProStrakan).

PHARMACOKINETICS — According to the manufacturer, the new patch releases 3.1 mg of granisetron by passive diffusion every 24 hours for up to 7 days. Granisetron serum concentrations peak about 48 hours after the patch is applied to the skin. The drug is metabolized in the liver, partly by CYP3A4, and excreted in urine and in feces.

CLINICAL STUDIES — An unpublished ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Granisetron Patch (Sancuso)
Article code: 1301d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian